Yokogawa Collaborates with Shell on Robotics and AI Technology for Plant Maintenance
Yokogawa Electric Corporation (TOKYO: 6841) announces that it has formalized a long-term agreement with Shell Global Solutions International B.V. ('Shell') to integrate and further develop technologies for utilizing robots and drones in plant monitoring and maintenance. Under the agreement, Yokogawa will add an advanced machine vision tool called Operator Round by Exception (ORE), developed by Shell, into its own OpreX™ Robot Management Core. The enhanced software service will be made available by Yokogawa to customers in the energy, chemicals, and other industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617976629/en/
OpreX Robot Management Core
ORE is a digital solution that uses machine vision and AI analytics to enable robots to autonomously perform a number of tasks in the operator round process, such as reading gauges and checking for leaks and machinery issues. It is the result of a two-year collaborative effort within Shell, which combined machine vision strategy with deep capabilities in the field of integrity management, remote site inspection, and corrosion management.
OpreX Robot Management Core is a key product in Yokogawa's robot solutions. The software helps customers maintain their facilities in a safer and more efficient manner by integrating the management of various types of robots that perform plant maintenance tasks conventionally carried out by humans. When connected to a plant's control and safety systems, the data acquired can be used to issue instructions to robots, thus enabling the first step to be taken toward autonomous plant operations. The addition of Shell's ORE technology will significantly increase the number of use cases available to customers through OpreX Robot Management Core.
Moving forward, Yokogawa robotics operations will deploy at two Shell facilities as a pilot into how robotics and drones can deliver value through efficiencies in plant monitoring and maintenance.
This collaboration is the first key milestone for Yokogawa working alongside Shell in the collaboration space at the Energy Transition Campus Amsterdam, which was created by Shell in 2022 to provide a platform for collaboration between companies, societal organisations, governments, and universities to work on tomorrow's energy solutions. Shell and Yokogawa have also agreed to collaborate on an aligned R&D roadmap to further develop and enhance the machine vision technology, ensuring continuous innovation and improvement. This collaboration underscores both companies' commitment to providing cutting-edge solutions to the energy and industrial sectors.
Masaharu Maeda, Yokogawa Electric vice president, executive officer, and head of the company's Solutions Business Division, stated, 'We are very excited to be working with Shell on this key technology field that promises to address the workforce challenges facing plant owners by significantly improving the efficiency of rounds in the field, while also reducing the inherent risk to operators. We look forward to making it available to industrial facility owners globally in the near future and contributing to safer and more efficient workplaces.'
'Shell & Yokogawa have a proud history of developing together to enable advanced automation solutions for our sites. With this agreement, we are taking our relationship to the next level. Robotics solutions combined with AI provide the potential to create a step change in productivity and safety,' said Gerben de Jong, CIO for Shell Integrated Gas, Upstream and Projects & Technology.
For More Information
Robot and Drone Technology:
https://www.yokogawa.com/solutions/featured-topics/robot-and-drone-technology/
About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,000+ employees in a global network of 128 companies spanning 62 countries.
For more information, visit www.yokogawa.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
11 minutes ago
- Business Wire
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced the successful completion of targeted enrollment for its Phase 2 HARMONIC™ clinical trial in Japan. The company enrolled 10 patients ahead of schedule across five clinical sites in Japan, including the National Cancer Center Japan. The HARMONIC™ trial is evaluating LP-300 in combination with carboplatin and pemetrexed in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The successful Japanese enrollment validates Lantern's strategic decision to expand the trial internationally to regions with significantly higher rates of never-smoker NSCLC patients such as Japan and Taiwan. "Completing our targeted enrollment in Japan ahead of schedule demonstrates excellent execution of our international expansion strategy and validates our decision to focus on regions where never-smoker NSCLC has the highest prevalence," said Panna Sharma, President and CEO of Lantern Pharma. "This achievement builds momentum as we continue enrollment in Taiwan and the United States, bringing us closer to generating the clinical data that could establish LP-300 as a treatment option for this underserved patient population with significant unmet medical need." The completion of Japanese enrollment represents an important milestone in the global HARMONIC™ trial, which is designed to enroll approximately 90 patients across multiple regions. Japan's notably higher rate of never-smoker NSCLC patients (33-40% of new cases) compared to Western populations (typically 15%) makes it a strategically important region for the trial. Similarly, Taiwan, where more than 50% of lung cancer cases occur in never-smokers, represents another key enrollment region. The HARMONIC™ trial previously demonstrated encouraging results in its initial safety lead-in cohort, showing an 86% clinical benefit rate and 43% objective response rate among the first seven patients enrolled in the United States. Notably, recent data revealed that one patient has achieved a durable complete response in target cancer lesions with survival continuing for nearly two years, demonstrating the potential for LP-300 to deliver meaningful long-term outcomes for never-smoker NSCLC patients. Never-smoker NSCLC is increasingly recognized as a distinct disease entity with unique clinical and genomic characteristics 1, representing a global market opportunity estimated at over $4 billion annually. Currently, there are no therapies specifically approved for never-smoker NSCLC patients, highlighting the significant unmet medical need this population faces. Lantern is actively exploring collaboration and partnering opportunities to maximize LP-300's commercial potential in multiple geographies. Lantern is scheduled to provide further clinical and outcome data from the HARMONIC™ trial later this quarter, with updates covering both Asian and U.S. patient cohorts. About LP-300 LP-300 is a disulfide small molecule and investigational drug candidate with a multimodal mechanism of action directed toward tyrosine kinase receptors and cell redox enzymes. It modulates cellular redox in key signaling pathways in NSCLC and directly engages with TKI receptors via cysteine modification. LP-300 has been evaluated in multiple Phase 1, 2, and 3 clinical trials in over 1,000 subjects, with retrospective analysis showing significant survival benefit in never-smoker lung adenocarcinoma patients. About the HARMONIC™ Trial The HARMONIC™ trial is a multicenter, open-label, randomized Phase 2 trial designed to evaluate the efficacy and safety of LP-300 in combination with standard-of-care chemotherapy (pemetrexed/carboplatin) versus chemotherapy alone in never-smoker NSCLC patients who have relapsed following TKI treatment. The trial is expected to enroll approximately 90 patients across sites in the United States, Japan, and Taiwan. The primary endpoints are progression-free survival (PFS) and overall survival (OS). For more information about the trial, visit or (NCT05456256). About Lantern Pharma: Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world. Please find more information at: Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024, under the investor SEC filings tab of our website at ( or on the SEC's website at ( Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. 1 Saito M, Shiraishi K, Matsumoto K, Schetter AJ, Ogata-Kawata H, Tsuchiya N, Kunitoh H, Nokihara H, Watanabe SI, Kamma H, Asamura H, Yamamoto S, Tan EM, Wang JY, Harris CC, Yokota J, Kohno T, Goto A. Lung cancer in patients who have never smoked — an emerging disease. PMC. 2024.
Business Wire
41 minutes ago
- Business Wire
Visa Cardholders Get First Shot at Applying for FIFA World Cup 26™ Tickets
WASHINGTON--(BUSINESS WIRE)--It's official: the road to the FIFA World Cup 26™ starts with Visa. As the Official Payment Technology Partner of FIFA and a global leader in digital payments, Visa cardholders with a Visa Debit, Credit or reloadable Visa prepaid cards globally will receive exclusive early access to apply for tickets to the most anticipated sporting event in the world. The first-ever Visa Presale Draw was announced at the Visa Payments Vault in Washington, D.C., where government officials from Canada, Mexico and the United States gathered to celebrate trilateral collaboration and the unifying power of sport at the Visa FIFA World Cup 26™ Reception. "The Visa Presale Draw offers Visa cardholders exclusive early access to enter the draw for tickets, creating an incredible opportunity for some lucky fans to secure their place at this historic event." Share 'The Visa Presale Draw offers Visa cardholders exclusive early access to enter the draw for tickets, creating an incredible opportunity for some lucky fans to secure their place at this historic event,' said Kim Lawrence, Regional President of North America at Visa. 'As we get closer to the tournament, Visa also plans to help communities and businesses across the continent get ready for the influx of travelers, ensuring the tournament's economic impact lasts far beyond the final whistle.' 'This is an unprecedented moment for Visa — not only are we redefining how fans experience the game, but we are also bringing them closer than ever with the opportunity to apply for exclusive ticket access through the first-ever Visa Presale Draw,' said Eduardo Coello, Regional President for Visa in Latin America and the Caribbean. 'As we set new standards for safe and secure payment experiences for fans, there's no better time to deliver on our promise than at the largest FIFA World Cup in history, right here in our region—with Mexico as a proud host.' Empowering Fans From September 10-19, fans with a Visa card, including Visa Credit, Visa Debit and reloadable Visa prepaid cards, can apply to enter the Visa Presale Draw – a randomized selection process that gives selected entrants the chance to purchase tickets before general ticket sales open. Interested cardholders will need a FIFA ID to participate in the Visa Presale Draw and are encouraged to visit today to create their ID, if they don't already have one. Those chosen to purchase tickets through the Visa Presale Draw will be notified by email starting no earlier than September 30 and given a dedicated time slot in October to purchase available tickets on a first come, first served basis. As the official payment method for FIFA ticketing, Visa will be the exclusive payment method accepted during the presale purchase window. Learn more about the Visa Presale Draw here. 'Excitement for the FIFA World Cup 26 is building fast, and 10 September is a date every football fan should have marked in their calendar,' said FIFA Chief Business Officer Romy Gai. 'We're delighted to once again partner with Visa to give fans the very first opportunity to apply for a place at the greatest show on earth. A ticket to the FIFA World Cup™ isn't just a ticket—it's a gateway to the most inclusive and spectacular tournament in our history. Everyone will want to be part of this moment, so make sure you've created your FIFA ID and have your Visa card ready.' Uplifting Communities and Small Businesses As Visa cardholders from around the world apply to secure exclusive ticket access for the FIFA World Cup 2026 TM, Visa also wants to help businesses get ready to make the most of the moment. By sharing trends and expertise, Visa will help empower local businesses, especially in host cities – from street vendors in Mexico City to boutiques in Kansas City, or a local bakery in Vancouver– so they can capitalize on World Cup tourism and turn tournament fanfare into lasting economic growth. More details on these programs will be shared as the match draw approaches. A Tournament Like No Other The FIFA World Cup 2026™ promises to be record-breaking: 48 teams, 104 matches over 39 days in 16 iconic host cities and will be the first ever tri-country hosted games across North America. With nearly 20 years of partnership with FIFA, Visa and FIFA continue to innovate and expand access for fans, business owners and communities alike. About Visa Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at
Hamilton Spectator
an hour ago
- Hamilton Spectator
PyroGenesis Receives Initial Contract for Titanium Metal Powder from European Additive Manufacturing Company
MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. ( ) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes advanced all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, today announces receipt of a contract for titanium metal powder produced by PyroGenesis' NexGen™ plasma atomization process, from a European engineering and material science firm specializing in the additive manufacturing industry. The name of the client and terms of the contract will remain confidential for competitive reasons. The client previously received and tested samples of PyroGenesis' metal powder. Today's contract announcement marks the first commercial order with this customer. The order is for a Ti64 'coarse' cut titanium metal powder, of the type that was recently qualified for use and added to the approved list of metal powders by a major global aerospace company. The powder for this order has already been produced and will be shipped to the customer over the next few weeks. Image: PyroGenesis' titanium metal powder as produced by its NexGen™ plasma atomization system. 'This initial order comes after a successful review and testing process with this European customer. The high standard of Ti64 metal powder produced at PyroGenesis Additive is the result of years of groundbreaking design and engineering work that went into developing our NexGen™ plasma atomization process, and the commercial results of these efforts are starting to appear,' said P. Peter Pascali, President and CEO of PyroGenesis. 'This customer is a key technology hub for their region, with state-of-the-art engineering and R&D. We hope to see further contracts that reflect the importance of the customer's role within the industry.' INDUSTRY AND MARKET CONTEXT PyroGenesis is the inventor of the plasma atomization process and in fact coined the term 'plasma atomization' in its original patent. The Company's NexGen™ system is a patented upgrade to what is considered the gold standard process for the development of metal powder for additive manufacturing, also referred to as metal 3D printing. PyroGenesis' development of high quality titanium metal powders is part of its three-vertical solution ecosystem that aligns with economic drivers that are key to global heavy industry. Metal powders are part of PyroGenesis' Commodity Security & Optimization vertical, where the development of advanced material production techniques, and the use of technology such as plasma to recover viable metals, chemicals, and minerals from industrial waste, helps to maximize raw materials and improve the availability of critical minerals. Titanium has been identified as a critical mineral by the Canadian government . The other verticals are Energy Transition and Emission Reduction, and Waste Remediation. About PyroGenesis Inc. PyroGenesis, a high-tech company, is a proud leader in the design, development, manufacture and commercialization of advanced plasma processes and sustainable solutions which reduce greenhouse gases (GHG) and are economically attractive alternatives to conventional 'dirty' processes. PyroGenesis has created proprietary, patented and advanced plasma technologies that are being vetted and adopted by multiple multibillion dollar industry leaders in four massive markets: iron ore pelletization, aluminum, waste management, and additive manufacturing. With a team of experienced engineers, scientists and technicians working out of its Montreal office, and its 3,800 m2 and 2,940 m2 manufacturing facilities, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The operations are ISO 9001:2015 and AS9100D certified, having been ISO certified since 1997. PyroGenesis' shares are publicly traded on the TSX in Canada (TSX: PYR), the OTCQX in the US (OTCQX: PYRGF), and the Frankfurt Stock Exchange in Germany (FRA: 8PY1). For more information, please visit: . Cautionary and Forward-Looking Statements This press release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'targets', 'expects' or 'does not expect', 'is expected', 'an opportunity exists', 'is positioned', 'estimates', 'intends', 'assumes', 'anticipates' or 'does not anticipate' or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur' or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management's current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by PyroGenesis as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the risk factors identified under 'Risk Factors' in PyroGenesis' latest annual information form, and in other periodic filings that it has made and may make in the future with the securities commissions or similar regulatory authorities, all of which are available under PyroGenesis' profile on SEDAR+ at . These factors are not intended to represent a complete list of the factors that could affect PyroGenesis. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. PyroGenesis undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQX Best Market accepts responsibility for the adequacy or accuracy of this press release. For further information please contact: Rodayna Kafal, Vice President, IR/Comms. and Strategic BD E-mail: ir@ RELATED LINK: 1 A photo accompanying this announcement is available at
